Evidence map
Pick a goal to see which peptides have been studied for it and how strong the evidence is.
Semaglutide Approved for type 2 diabetes and chronic weight management, with large randomized trials including a cardiovascular outcomes trial. FDA-approved
Tirzepatide Approved for type 2 diabetes and chronic weight management, with large randomized trials and a head-to-head against semaglutide. FDA-approved
CJC-1295 Small controlled trials in healthy volunteers showed it raises GH and IGF-1. No trial has shown it improves muscle, fat loss, recovery or aging. Human trials
Ipamorelin Phase 1 pharmacology in volunteers and one phase 2 trial in post-surgical ileus that did not meet its primary endpoint. Nothing on muscle, fat or anti-aging. Human trials
BPC-157 Hundreds of rodent studies, mostly from one research group. Human data amounts to three small pilot reports (knee pain, interstitial cystitis and a two-person IV safety pilot). Animal studies only
TB-500 TB-500 itself has essentially no human trials. Full-length thymosin beta-4, a related but different molecule, has been tested in small clinical trials for the eye and heart. Animal studies only
GHK-Cu Strong lab data and some animal wound-healing work. Reviews note a "surprising absence" of clinical studies of GHK-Cu in wrinkle products, and no human data for injection. Animal studies only
Strength bars show the best evidence tier reached, not whether the peptide works.